Bruce Booth DPhil

Bruce is a partner at Atlas Venture and focuses on the discovery and development of novel therapeutics. Since joining in 2005, Bruce has been involved in the founding and funding of a number of innovative companies with a particular focus on forming unique, innovative, and capital efficient models for drug R&D.
,br/> He is a co-founder/founding investor and current chair of the boards of miRagen Therapeutics, Nimbus Therapeutics, Padlock Therapeutics, Quartet Medicine, and Rodin Therapeutics. He serves on the boards of Zafgen, Lysosomal Therapeutics Inc., and several other seed-stage biotech companies. Prior to joining Atlas, Bruce was an investor with Caxton Health Holdings and a consultant at McKinsey & Company, where he helped to build the Pharma R&D practice. He received a D.Phil. (PhD) from Oxford University as a Marshall Scholar and a Bachelor of Science from The Pennsylvania State University.